Denali Therapeutics
DNLI · NASDAQ
Bulios Fair Price
$11.07
45.9% downside
Current Price
$20.47
According to Bulios Fair Price, DNLI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Denali Therapeutics Inc. is a biotechnology company focused on developing therapeutics for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. The company specializes in discovering new drug candidates that can effectively cross the blood-brain barrier and target biological pathways associated with the progression of these diseases. Denali utilizes advanced technologies, including Blood-Brain Barrier Penetration, which allows for targeted delivery of drugs directly to the central nervous system, enhancing the efficacy of treatments.
Sector
Healthcare
Industry
Biotechnology
CEO
Ryan J. Watts
Employees
503
Headquarters
South San Francisco
Upcoming events
Earnings
Upcoming earnings report